ストックスクリーナーアプリを入手
1.99
0.00%
0.00
プレマーケット:
1.99
前日終値:
$1.99
開ける：
$2.02
24時間の取引高:
747.34K
Relative Volume:
0.81
時価総額：
$199.65M
収益：
-
当期純損益:
$-299.80M
株価収益率:
-0.7007
EPS:
-2.84
ネットキャッシュフロー:
$-217.49M
1週間 パフォーマンス:
-5.24%
1か月 パフォーマンス:
-36.83%
6か月 パフォーマンス:
-69.43%
1年 パフォーマンス:
-66.27%
1日の値動き範囲:
$1.91
$2.03
1週間の範囲:
$1.91
$2.16
52週間の値動き範囲:
$1.91
$8.885
Acelyrin Inc Stock (SLRN) Company Profile
SLRN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLRN
Acelyrin Inc
|
1.99 | 199.65M | 0 | -299.80M | -217.49M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-07-08 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-08 | 開始されました | Citigroup | Neutral |
| 2023-09-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-09-05 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-30 | 開始されました | Jefferies | Buy |
| 2023-05-30 | 開始されました | Morgan Stanley | Overweight |
| 2023-05-30 | 開始されました | Piper Sandler | Overweight |
| 2023-05-30 | 開始されました | TD Cowen | Outperform |
すべてを表示
Acelyrin Inc (SLRN) 最新ニュース
JPMorgan Chase & Co. Cuts Stake in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by JPMorgan Chase & Co. - MarketBeat
Barclays PLC Buys 65,188 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin spikes on upcoming mid-stage data update on eye disease drug - MSN
SLRN Stock Hits 52-Week Low at $2.2 Amid Market Challenges - Investing.com Nigeria
ACELYRIN reports progress in thyroid eye disease treatment By Investing.com - Investing.com Nigeria
Q1 Earnings Forecast for Acelyrin Issued By HC Wainwright - Defense World
HC Wainwright Predicts Acelyrin's Q1 Earnings (NASDAQ:SLRN) - MarketBeat
HC Wainwright Lowers Acelyrin (NASDAQ:SLRN) Price Target to $6.00 - Defense World
Acelyrin falls after updating mid-stage trial data for eye disease drug - MSN
Acelyrin stock plunges after positive Phase II data readout in thyroid eye disease - Yahoo Finance
Acelyrin To Take Tepezza Competitor Into Phase III In TED - Citeline News & Insights
Citigroup Has Lowered Expectations for Acelyrin (NASDAQ:SLRN) Stock Price - MarketBeat
Citi cuts Acelyrin stock target amid uncertainty in Phase 3 program - Investing.com Canada
Stock market news: ACELYRIN -34.67%, Vuzix -21.58% among biggest losers during mid day trading - Business Upturn
Citi cuts Acelyrin stock target amid uncertainty in Phase 3 program By Investing.com - Investing.com South Africa
Stock market today: Acelyrin -40.40%, Amesite -30.92% among biggest losers in early trading - Business Upturn
Stock market today: XTI Aerospace surged by 108.52% while ACELYRIN posted fall of 38.68% in early trading - Business Upturn
Acelyrin stock falls after TED drug data (SLRN:NASDAQ) - Seeking Alpha
H.C. Wainwright cuts Acelyrin stock target, keeps neutral on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Acelyrin stock target, keeps neutral on trial data - Investing.com
Jane Street Group LLC Decreases Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin stock: Piper Sandler bullish on longigutamab TED treatment potential - Investing.com India
ACELYRIN advances lonigutamab into Phase 3 for TED treatment - Investing.com India
ACELYRIN reports progress in thyroid eye disease treatment - Investing.com
Updated: Acelyrin’s stock drops due to mixed Phase 2 data in thyroid eye disease - Endpoints News
Acelyrin announces additional lonigutamab data, design for LONGITUDE program - TipRanks
Acelyrin (SLRN) Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease - StreetInsider.com
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in - The Bakersfield Californian
ACELYRIN's Thyroid Eye Disease Drug Shows Promise in Phase 2, Advances to Pivotal Trials - StockTitan
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024 - MSN
Acelyrin Leads The Charge With 2 Other US Penny Stocks - Yahoo Finance
Acelyrin stock spikes on upcoming data update (SLRN:NASDAQ) - Seeking Alpha
What's Going On With ACELYRIN Shares Friday? - Benzinga
Barclays PLC Purchases 65,188 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Purchased by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Grows Stock Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab - The Manila Times
ACELYRIN to Present Pivotal Phase 2 Data for Breakthrough Thyroid Eye Disease Treatment - StockTitan
SLRN stock touches 52-week low at $3.06 amid market challenges - Investing.com Australia
Franklin Resources Inc. Grows Stake in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Why Is Acelyrin, Inc. (SLRN) Among the Best Biotech Penny Stocks to Invest in Now? - Insider Monkey
12 Best Biotech Penny Stocks To Invest In Now - Insider Monkey
Acelyrin Inc (SLRN) 財務データ
収益
当期純利益
現金流量
EPS
Acelyrin Inc (SLRN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lin Shao-Lee | Chief Executive Officer |
Apr 01 '24 |
Sale |
6.63 |
9,961 |
66,024 |
1,577,374 |
| Lin Shao-Lee | Chief Executive Officer |
Feb 20 '24 |
Sale |
7.60 |
15,701 |
119,403 |
1,587,335 |
4.81%
大文字化:
|
ボリューム (24 時間):